First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...